Drug Profile
Gartisertib - Merck KGaA
Alternative Names: M-4344; MSC2580591A; VRT 1228692; VX-803Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Developer Merck KGaA
- Class Amides; Amines; Antineoplastics; Fluorobenzenes; Piperazines; Piperidines; Pyrazolones; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action ATR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lymphoma; Solid tumours
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease, Second-line therapy or greater) in Netherlands (PO)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease, Second-line therapy or greater) in Spain (PO)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease, Second-line therapy or greater) in United Kingdom (PO)